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Synthesis of Novel Aza-aromatic Curcuminoids with
Improved Biological Activities towards Various Cancer Cell
Lines
Atiruj Theppawong,[a] Tim Van de Walle,[a] Charlotte Grootaert,[b] Margot Bultinck,[a]
Tom Desmet,[c] John Van Camp,*[b] and Matthias D’hooghe*[a]
1. Introduction
Curcumin, isolated from a local plant in Asia and also known
as the golden spice, is frequently used as a food additive.
Chemically, the structure of curcumin features two vanillyli-
dene groups, keto–enol tautomerism, and a conjugated
system (Figure 1), and this molecule was successfully prepared
for the first time in excellent yield by Pabon in 1964.[1] In that
respect, the use of boron complexed with acetylacetone was
shown to produce symmetrical curcumin derivatives efficiently.
Since then, several publications have described how this pro-
cedure can be to applied to prepare a diversity of related
target compounds.[1,2] From a biological point of view, curcu-
min displays multiple activities, especially in the field of oncol-
ogy.[3] Moreover, curcumin has long been considered to be an
ideal compound to treat cancer due to several reports high-
lighting its nontoxicity for mammals, even at high doses.[4] De-
spite the established benefits of curcumin, it still suffers from
limited bioavailability, fast metabolism in the body, and rather
aspecific activity.[5] To circumvent these problems and to im-
prove its pharmacological properties, many reported ap-
proaches focus on the introduction of structural modifications
of the curcumin scaffold to deliver new analogues.[6] In that re-
spect, previous work in our group aimed at the preparation of
nitrogen curcumin analogues and involved modification of the
labile b-diketone moiety by synthesizing new b-enaminone
curcuminoids by using both alkylamines and more polar
amines.[7] The obtained N-alkyl b-enaminones showed higher
cytotoxicity than curcumin, but similar water solubility. On the
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Curcumin, a natural compound extracted from the rhizomes of
Curcuma longa, displays pronounced anticancer properties but
lacks good bioavailability and stability. In a previous study, we
initiated structure modification of the curcumin scaffold by imi-
nation of the labile b-diketone moiety to produce novel b-en-
aminone derivatives. These compounds showed promising
properties for elaborate follow-up studies. In this work, we fo-
cused on another class of nitrogen-containing curcuminoids
with a similar objective: to address the bioavailability and sta-
bility issues and to improve the biological activity of curcumin.
This paper thus reports on the synthesis of new pyridine-,
indole-, and pyrrole-based curcumin analogues (aza-aromatic
curcuminoids) and discusses their water solubility, antioxidant
activity, and antiproliferative properties. In addition, multivari-
ate statistics, including hierarchical clustering analysis and prin-
cipal component analysis, were performed on a broad set of
nitrogen-containing curcuminoids. Compared to their respec-
tive mother structures, that is, curcumin and bisdemethoxycur-
cumin, all compounds, and especially the pyridin-3-yl b-enami-
none analogues, showed better water solubility profiles. Inter-
estingly, the pyridine-, indole-, and pyrrole-based curcumin de-
rivatives demonstrated improved biological effects in terms of
mitochondrial activity impairment and protein content, in addi-
tion to comparable or decreased antioxidant properties. Over-
all, the biologically active N-alkyl b-enaminone aza-aromatic
curcuminoids were shown to offer a desirable balance be-
tween good solubility and significant bioactivity.
Figure 1. Structure of curcumin.
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other hand, more polar b-enaminone curcumin derivatives dis-
played significantly improved water solubility and comparable
bioactivities against undifferentiated cancer cells, in addition to
no toxicity against differentiated intestinal cells. The rationale
to introduce a b-enaminone moiety was related to the broad
biological relevance of b-enaminones in general, including for
example, antimicrobial,[8] anticonvulsant,[9] and antitumor/anti-
cancer properties.[7, 10]
Up to now, the replacement of the aromatic moiety of cur-
cumin with an aza-heteroaromatic alternative—another way to
introduce nitrogen—has been rarely envisaged in curcumin
chemistry. Only a few isolated examples have been reported in
the literature so far,[11] and these compounds are poorly docu-
mented in terms of their synthesis, characterization, physical
properties, and bioactivities. Therefore, in this work, a set of
new aza-heteroaromatic curcumin analogues was synthesized
to address the low water solubility of curcumin, without com-
promising its pronounced bioactivities. Because of the good
results obtained previously for b-enaminone derivatives, b-en-
aminone aza-aromatic curcuminoids were synthesized as well
by using different amines. All of these new aza-heteroaromatic
analogues were evaluated in a next stadium for their in vitro
biological behavior, water solubility, and antioxidant capacity.
Finally, multivariate statistics were performed on a broad set of
nitrogen-containing curcuminoids to shed more light on struc-
ture–property relationships.
2. Results and Discussion
In this work, aza-heteroaromatic curcumin analogues were suc-
cessfully prepared by using carefully optimized reaction condi-
tions (Table S1, Supporting Information). Three different alde-
hydes were selected to synthesize the desired structures : pyri-
dine-3-carboxaldehyde, indole-3-carboxaldehyde, and pyrrole-
2-carboxaldehyde. Boron complexation (B2O3) with acetylace-
tone (1) was deployed to protect the active methylene unit
and to avoid the typical side reaction (i.e. formation of a C3
Knoevenagel product). The reactions were performed in ethyl
acetate at 80 8C for at least 4 h and were monitored by TLC or
LC–MS to reach maximum conversion. Relative to the reaction
time required for bis-pyridine 2 (4 h), longer reaction times
were required for bis-indole 3 (20 h) and bis-pyrrole 4 (18 h) to
obtain the desired products in yields of 9 and 20%, respective-
ly (Table S1). However, for compounds 3 and 4, the reaction
was alternatively performed in acetonitrile by using piperidine
as a base, which provided improved yields of 49 and 66%, re-
spectively (Scheme 1). To obtain the pure products, the crude
mixtures were purified by silica gel column chromatography
followed by recrystallization from methanol. Subsequently, bis-
pyridine 2 was selected to be used in the synthesis of the cor-
responding b-enaminone derivatives. As established in our pre-
vious studies, the use of montmorillonite K10 (MK10), in com-
bination with microwave irradiation, provides a convenient
method to prepare b-enaminone curcuminoids.[7] Thus, the
proposed imination of structure 2 was performed accordingly
with either methoxyalkyl-, hydroxyalkyl-, or alkylamines (RNH2)
and 2.4 equivalents of acetic acid in the presence of MK10
(Scheme 2, Table 1). Several attempts were made to optimize
the reaction conditions towards the synthesis of b-enaminone
pyridin-3-yl curcumin analogues 5a–f. The reaction was con-
ducted in 2-methyltetrahydrofuran (2-MeTHF) or ethanol at
80–85 8C for 75–105 min. Although full conversion was always
reached, the amount of amine added (2.5–10 equiv.) had to be
optimized for each amine separately. In some cases, polar
amines triggered the formation of cyclic side products (i.e.
compounds 6d and 6 f), for which the reaction mechanism is
described in previous work.[7b] The ratio of b-enaminones 5d
or 5 f versus dihydropyridin-4-ones 6d or 6 f was found to be
1.5–2.3 (Scheme 2). A longer reaction time (105 min) apparent-
ly stimulated this cyclization reaction, and as described before,
the use of ethanol was also observed to activate pyridinone
formation under microwave irradiation (Table 1).[7b]
The obtained curcuminoids were then purified by column
chromatography to obtain compounds 5a–f, 6d, and 6 f in
rather low yields (6–24%) but excellent purity. As can be no-
ticed, a substantial amount of product was inevitably lost
during either normal- or reverse-phase column chromatogra-
phy.
With the aim to improve the water solubility and bioactivity
and to extend the available compound library, new aza-hetero-
Scheme 1. Synthesis of aza-heteroaromatic curcumin analogues 2–4.
Scheme 2. Synthesis of b-enaminones 5a–f and cyclic products 6d and 6 f.
Table 1. Reaction conditions and yields for the synthesis of b-enami-
nones 5a–f and cyclic products 6d and 6 f.
Compd R RNH2 [equiv.] T [8C] Time [min] Yield [%]
5a iBu 5 80[a] 75 24
5b cyclohexyl 10 80[b] 90 6
5c (CH2)2OMe 5 80
[b] 75 16
5d (CH2)3OMe 2.5 85
[b] 105 24
5e (CH2)2OH 5 80
[b] 75 12
5 f (CH2)3OH 2.5 85
[b] 105 16
6d (CH2)3OMe 2.5 85
[b] 105 16
6 f (CH2)3OH 2.5 85
[b] 105 7
[a] Using 2-MeTHF. [b] Using EtOH.
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aromatic curcumin analogues 2–4, b-enaminone analogues
5a–f, and dihydropyridin-4-ones 6d and 6 f were thus pro-
duced in this work. All compounds had a purity of 95%,
which was determined by NMR spectroscopy and LC–MS anal-
ysis. Afterwards, these molecules were examined in terms of
their water solubility to support the rationale of this work. The
main reason behind the applied structure modification was to
improve the solubility and hence to avoid in vitro precipitation
of compound dilutions and more specifically to increase their
bioaccessibility (because higher aqueous solubility usually re-
sults in better oral bioavailability). Curcuminoids may be ab-
sorbed through the gastrointestinal tract through a combina-
tion of processes including passive diffusion and active trans-
port. In that respect, the water solubility of compounds 2–6
was analyzed by using a colorimetric-technique-based assay at
two different time points (90 min and 24 h) to make sure that
the solubility values reached the maximum concentration for
each compound. An excess amount of solid was dissolved in a
phosphate buffer at pH 6.8 by using the shake flask method,
which is commonly used to determine aqueous solubility.[7b,12]
The experiments were designed for 24 h at 37 8C average body
temperature. The values were obtained on the basis of linear
regression of each standard curve, which was independently
triplicated. The results show that the solubilities of modified
compounds 2–6 are all higher than that of curcumin, as shown
in Table 2. Specifically, aza-aromatic curcumin analogues
showed a 3- to 28-fold increase in water solubility, whereas
pyridine-based b-enaminone curcumin analogues 5a–f demon-
strated significantly improved solubility in the range of 4- to
1600-fold. Specifically, b-enaminones with polar amines dis-
played extremely high aqueous solubility. Moreover, com-
pounds 6d and 6 f showed high water solubility in buffer
medium, in the same range as that of their respective b-enami-
nones 5d and 5 f. These results imply that the modification
successfully addressed one of the main goals of our work,
which was to obtain derivatives with improved aqueous solu-
bility.[7] Therefore, these results can contribute to minimized
precipitation issues in a biological medium for anticancer eval-
uation, which is beneficial within the framework of bioavailabil-
ity studies.
Because curcumin is known to exert interesting antioxidant
activities, the antioxidant properties of the newly synthesized
aza-heteroaromatic curcumin analogues were determined by
using the DPPH (1,1-diphenyl-2-picrylhydrazyl) radical-scaveng-
ing activity assay and the ferric reducing antioxidant power
(FRAP) assay.[12] Trolox and a-tocopherol were used as antioxi-
dant positive controls (for the DPPH and FRAP assays, respec-
tively&&ok?&& ). The DPPH and FRAP assays are commonly
used primarily to evaluate the chemical antioxidant properties.
The DPPH scavenger assay is based on the neutralization of
the stable DPPH radical and determines the percentage inhibi-
tion of radical activity. On the other hand, the FRAP assay is
based on the reduction of the ferric(III)–tripyridyltriazine com-
plex (Fe3+–TPTZ) to the ferrous form (Fe2+–TPTZ) and is ex-
pressed as Trolox equivalents. The results of the chemical anti-
oxidant capacity tests are described in Table 1. From all aza-ar-
omatic curcumins, bis-pyridine 2 showed no activity, whereas
compounds 3 and 4 could not be evaluated by the DPPH
assay due to the saturation of the selected wavelength (l=
515 nm) for this experiment (see the Supporting Information).
Therefore, an alternative method was deployed (using FRAP),
and bis-pyrrole 4 (0.79 Trolox equivalent per mm) showed activ-
ity comparable to that of a-tocopherol&&ok?&&, whereas
bis-indole 3 (0.27 Trolox equivalent per mm) showed antioxi-
dant properties that were lower than those of the controls.
This could be explained by the fact that the free NH function-
ality on the aza-heteroaromatic ring can be equipotent to the
hydroxy groups in the curcumin scaffold. Compounds 5 and 6
showed no/lower antioxidant activity than curcumin and the
positive controls, probably because these structures do not
contain a hydroxy group on the pyridinyl curcumin core. Com-
pounds 5e and 5 f, containing a hydroxy moiety in the b-en-
aminone nitrogen substituent, showed slightly lower activity
upon the FRAP experiment (0.04 Trolox equivalent per mm),
whereas the median effective concentration (EC50) values
under the highest concentration (200 mm) could not be ob-
served as explicitly upon performing the DPPH experiment.
The lack of phenolic groups (due to the replacement of the ar-
omatic part of curcumin with a pyridin-3-yl scaffold) resulted in
complete abolition of the antioxidant activity in both assays,
which further supports the established importance of the free
phenolic (or amino) groups if antioxidant properties are de-
sired.
Next to these antioxidant properties, curcuminoids have
shown a wide range of other biological activities, in particular
anticancer effects.[3b,d, f, 13] Therefore, different cell lines were
subjected to newly synthesized nitrogen curcuminoids 2–6
and were analyzed through in vitro cell-based assays for pro-
tein content as a marker for cell growth (sulforhodamine B,
SRB), mitochondria activity [3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide, MTT], and intracellular reactive
oxygen species (ROS) production (2’,7’-dichlorodihydrofluores-
cein diacetate, DCFH-DA) to evaluate their cytotoxic effects.
Table 2. Determination of solubility experiments in 0.1m phosphate
buffer pH 6.8 and evaluation of chemical antioxidant capacity using FRAP
assays.[a]
Compd Solubility in 0.1 m phosphate
buffer pH 6.8 [mm]
FRAP [Trolox equiv
per mm]
90 min 24 h
curcumin 2.90.3 2.600.0 1.11
a-tocopherol – – 0.76
Trolox – – –
2 12.40.2 9.20.1 0.03
3 19.00.2 11.10.1 0.27
4 84.82.8 74.21.3 0.79
5a 168.46.0 303.016.0 0.03
5b 11.30.6 12.20.6 0.00
5c 895.018.0 2282.5174.0 0.00
5d 897.41.1 2313.590.0 0.01
5e 4350.8260.0 4847.2140.0 0.04
5 f 1472.824.0 4270.5332.0 0.04
6d 1283.161.2 2981.7165.8 0.00
6 f 2462.657.2 4999.0136.8 0.00
[a] n=3 triplicate independent experiments.
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Cancer cell lines included human-derived intestinal cells (HT-29
and Caco-2), endothelial cells (EA.hy926), a hepatoma cell line
(HepG2), and a Chinese hamster ovarian cell line (CHO-K1).
Doxorubicin was used as a positive control for MTT and SRB
experiments, whereas in the ROS experiments, the ROS inhibi-
tor N-acetyl-l-cysteine (NAC) was used as experiment control.
The IC50 values obtained through MTT and SRB are shown in
Table 3. Based on the observations made, different cell lines re-
sulted in different median inhibitory concentration (IC50)
values, strongly depending on the cell type. Interestingly, aza-
aromatics 2–4 showed higher mitochondrial activity/growth in-
hibition (MTT) than their mother compound curcumin. To sup-
port these results, a protein content experiment (SRB) was
then performed, and the results pointed to the same trend as
that observed for the MTT assay, which confirmed that aza-het-
eroaromatic analogues 2, 3, and 4 exhibit significantly stronger
cell growth inhibition effects than curcumin. On the other
hand, b-enaminones 5a–d demonstrated moderate growth in-
hibition, whereas 5e and 5 f showed no activity at maximum
concentration (75 mm). In terms of their water solubility, b-en-
aminones 5a–f performed better than aza-heteroaromatic ana-
logues 2–4 and curcumin. No solids were observed after an in-
cubation time of 72 h for the MTT and SRB assays for com-
pounds 5a–f. Thus, it seems that the more soluble compounds
exert decreased cytotoxicity due to a low cell membrane per-
meability effect, which will be elaborated further on. Moreover,
dihydropyridin-4-ones 6d and 6 f showed a trend similar to
that shown by 5e and 5 f concerning their bioactivity and
water solubility. Thus, the aim to improve water solubility was
successfully reached for all structures, whereas the bioactivity
towards cancer cells was slightly lower for b-enaminones 5a–f
and considerably higher for aza-aromatics 2–4. In contrast, di-
hydropyridin-4-ones 6d and 6 f showed no interesting cytotox-
icity, pointing to the importance of conserving the linear cur-
cumin scaffold if cancer-cell proliferation is targeted. Thus, the
introduction of a nitrogen atom in the aromatic moiety of the
curcumin scaffold has a positive influence on the antiprolifera-
tive properties of curcumin, provided that the conjugated cur-
cumin structure remains intact. Although aza-heteroaromatic
b-enaminones 5a–f, especially the most polar ones, show
slightly lower (yet still significant) cytotoxic effects than non-b-
enaminone template compound 2, the installation of a b-en-
aminone moiety is desired, because this increases the stability
of the curcumin scaffold.[7b,14] In other words, further optimiza-
tion of this class could focus on minor modifications of the ni-
trogen side chain to arrive at compounds with even better bio-
activity, water solubility, and stability. Within our series of six
aza-heteroaromatic b-enaminone derivatives, compound 5a
demonstrated the highest antiproliferative activity—almost
comparable to the activity of curcumin—and will therefore be
used as a lead compound for the synthesis of new b-enami-
nones in future work.
In the next set of experiments, intracellular ROS was as-
sessed in different cell lines because of their possible role in
cytotoxicity-related pathways. The imbalance between ROS
and antioxidant levels could lead to the development of cell
damage and health issues, including chronic diseases.[15]
Higher ROS levels are considered as toxic and sequentially
cause DNA damage and, therefore, increase the risk in the first
stage of cancer development.[16] Moreover, high ROS produc-
tion may also cause cell apoptosis by stimulation of the intrin-
sic mitochondrial pathway, which induces outer membrane
permeabilization and releases apoptotic proteins.[17] An antioxi-
dant diet, for example, phenolic compounds, can trigger a re-
duction in the amount of ROS produced&&ok?&&, which is
consequently beneficial for treating several human diseases, in-
cluding neurodegenerative diseases,[18] aging,[19] inflammatory
injuries,[20] and cancer.[21] It is worth considering whether the
observed cytotoxicity of curcuminoids may be correlated to
the induction of intrinsic mitochondrial pathways by high ROS
production. It is possible that the a,b-unsaturated ketone
moiety can serve as a biological Michael acceptor that cova-
Table 3. Cell growth inhibition of 2–4, 5a–f, 6a, and 6b measured after 72 h treatment by using mitochondria activity (MTT) and protein content (SRB) as-
says.[a]
Compd Caco-2 IC50 [mm] EA.hy926 IC50 [mm] HT-29 IC50 [mm] HepG2 IC50 [mm] CHO-K1 IC50 [mm]
MTT SRB MTT SRB MTT SRB MTT SRB MTT SRB
Cur 28.06.4 33.14.5 20.05.9 34.710.5 23.45.1 20.31.1 20.34.1 21.34.0 21.38.9 33.52.3
Dox 11.11.0 12.10.8 1.40.5 1.40.3 4.00.9 3.50.4 5.51.4 2.51.2 1.40.5 6.21.7
N-acetyl-l-cysteine >75 >75 – – – – – – – –
2 6.92.5 7.33.1 7.91.9 11.22.8 8.20.8 6.13.4 8.30.7 10.01.6 7.20.3 10.52.1
3 3.30.3 2.10.6 11.74.6 15.25.9 11.56.7 15.36.6 10.01.7 10.41.5 7.91.3 12.15.6
4 7.51.6 9.70.6 8.30.9 9.02.2 8.90.5 9.60.5 8.20.9 9.81.5 6.93.0 11.72.7
5a 45.310.5 31.69.0 33.09.5 35.97.2 37.61.8 30.910.9 26.20.3 20.81.5 17.74.4 28.67.7
5b 65.62.1 60.86.0 40.21.4 53.01.9 36.47.9 19.40.9 >75 >75 16.81.1 20.40.6
5c 53.80.6 49.10.6 60.010.5 63.08.3 55.312.5 46.015.8 56.73.7 66.41.3 45.16.6 71.75.1
5d 28.53.5 36.00.1 70.62.5 72.73.7 59.67.7 51.56.1 >75 >75 21.33.7 24.11.7
5e >75 >75 >75 >75 >75 >75 >75 >75 >75 >75
5 f >75 >75 >75 >75 >75 >75 >75 >75 >75 >75
6d >75 >75 >75 >75 >75 >75 >75 >75 >75 >75
6 f >75 >75 >75 >75 >75 >75 >75 >75 >75 >75
[a] Data are presented as mean standard deviation. Combination data of MTT and SRB from two different students on curcumin analogues (n6).&
&ok?&&
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lently binds to the thiol residues (SH) of cysteine compart-
ments in different proteins and initially triggers cascade signal-
ing apoptosis pathways.[22] To study the impact of novel deriva-
tives 2–6, a fluorescent-based technique was conducted by
using DCFH-DA, which is commonly used as a probe for oxida-
tive stress. In this work, two concentrations of curcuminoids
were tested, 10 (high) and 1 mm (mild), and they parallel
plasma concentrations of curcumin in a previous study.[23]
Moreover, ROS experiment results were analyzed in correlation
to protein content (SRB) to normalize the ROS production
values, as formerly observed MTT and SRB values showed that
some IC50 values were lower than 10 mm. Moreover, as previ-
ously reported, the ROS response in the EA.hy926 cell line was
pro-oxidative,[7a] whereas for intestinal cell lines (Caco-2 and
HT-29), intracellular ROS response was decreased in some
cases. In both HepG2 and CHO-K1, some compounds had an
antioxidative effect.[7] In this study, at 10 mm treatment, aza-aro-
matics 2–4 all showed a strong response (intracellular ROS
products) in the five different cancer cells, whereas at 1 mm,
bis-indole 3 demonstrated increased ROS production in two
different cell lines, HT-29 and HepG2. Moreover, bis-pyrrole 4
exhibited a trend similar to that exhibited by compound 3 but
on different cells, Caco-2 and EAhy926, whereas decreased
ROS generation was observed in HepG2 (indicating an antioxi-
dant effect). For b-enaminones 5a–f, the increase/decrease in
ROS depended on the cell type. In Caco-2, compounds 5a–e
showed moderate to high ROS generation at 10 mm, whereas
no increase/decrease in ROS production could be noticed at
1 mm. In contrast, in EAhy.926 and CHO-K1 cells, the ROS re-
sponse slightly decreased upon applying 5a–c, 5e, and 5 f in-
dependently at 1 mm. Moreover, HT-29 and HepG2 cells, at
10 mm, were observed to provoke an antioxidant effect that
minimized ROS production for 5a–c, 5e, and f. For dihydropyr-
idin-4-ones 6d and 6 f, ROS production was not remarkably
visible in five different cell lines at both concentrations relative
to that observed for nontreated cells. A control in these experi-
ments was NAC, a ROS inhibitor,[24] which induced a significant
decrease in ROS generation in the intestinal cell lines (Caco-2
and HT-29), the endothelial cell line (EA.hy926), and the hepa-
toma cell line (HepG2). Only in CHO-K1 cells was an increase
observed, as shown in Table 4. It is often difficult to compare
results with other studies because of the different parameters
used in the experimental procedures, such as cell line types,
molecules, concentrations, and incubation periods.[25] To our in-
terpretation, increased cellular ROS was observed at a 10 mm
concentration for bis-indole 3 and bis-pyrrole 4 in five different
cell lines, whereas bis-pyridine 2 showed a trend similar to that
of the other two aza-aromatic curcuminoids, except in HepG2
cells. The reason behind the different results in HepG2 cells
may be related to their robustness and detoxification mecha-
nisms.[26] Moreover, b-enaminones 5a–f showed increased cel-
lular ROS in Caco-2 at 10 mm, whereas other cell lines were ob-
served to display either decreased cellular ROS or no difference
relative to nontreated cells (control). At 10 mm, compounds 5c,
5d, and 5 f exhibited significantly decreased ROS in HepG2
cells, whereas compounds 5a–c showed decreased ROS in HT-
29 cells. At 1 mm, in EA.hy926, decreased ROS generation was
observed in 5b, 5c, and 5 f, whereas in compounds 5a–c, 5e,
and 5 f it was observed in CHO-K1 cells. However, dihydropyri-
din-4-ones 6d and 6 f showed no activity at both test concen-
trations (10 and 1 mm). Therefore, our results remarkably dem-
onstrate the pro-oxidative effect of aza-aromatic curcumin ana-
logues 2–4, whereas b-enaminones 5a–f show both pro-oxida-
tive and antioxidative effects depending on the cell types. It
can be concluded that there might be a correlation between
the cytotoxicity effects of aza-aromatics 2–4 and overproduc-
tion of ROS, which was preliminary observed in MTT and SRB,
suggesting that these compounds induce cytotoxic effects
through ROS-mediated apoptosis pathways. Nonetheless, in
the case of b-enaminones 5a–f and dihydropyridin-4-ones 6d
and 6 f, no explicit link can be noted between cell viability and
pro- or antioxidant activities, and other pathways might be in
play as well. In these cases, the increased/decreased intracellu-
lar ROS levels were strongly cell line/compound specific.
Table 4. Intracellular ROS, expressed as percentage compared to the untreated control cells (n3) with protein content normalization (ROS/SRB).[a]
Compd Caco-2 EA.hy926 HT-29 HepG2 CHO-K1
10 mm 1 mm 10 mm 1 mm 10 mm 1 mm 10 mm 1 mm 10 mm 1 mm
Cur 95.82.5 96.75.8 103.97.6 99.96.4 90.26.1[b] 92.85.8[b] 84.28.1[b] 95.913.8 91.95.2[b] 88.716.2
N-acetyl-l-
cysteine
47.82.6[c] 55.75.8[c] 79.67.4[b] 79.611.1[b] 87.73.7[b] 90.112.0[b] 70.53.1[c] 73.12.7[b] 102.25.4 102.40.8
2 142.711.9[b] 104.815.1 116.13.3[b] 111.51.6[b] 127.07.9[b] 94.04.0 90.411.9 99.04.6 110.54.5[b] 100.84.3
3 110.36.5[b] 95.77.3 217.820.3[b] 110.67.5 125.212.0[b] 141.421.3[b] 382.234.0[c] 129.18.0[c] 109.14.9[b] 96.42.6
4 124.38.7[c] 110.29.5[b] 165.118.9[b] 295.238.5[c] 120.78.7[b] 104.66.3 120.926.1 75.614.6[b] 116.74.9[b] 101.64.9
5a 114.73.1[b] 109.87.4 93.414.6 88.79.3 84.12.5[b] 102.911.1 94.04.6 90.713.7 85.52.6[c] 83.84.7[b]
5b 117.75.6[b] 101.30.9 113.99.5 89.14.2[b] 90.62.8[b] 93.713.2 98.84.6 92.37.8 90.52.5[b] 78.43.3[c]
5c 243.217.5[b] 102.48.8 89.52.7[b] 83.76.7[b] 88.13.6[b] 100.25.8 88.45.3[b] 94.84.0 96.210.1 84.16.5[b]
5d 110.65.3[b] 101.59.2 98.32.0 101.65.8 95.114.0 102.519.4 89.43.1[b] 92.34.6 97.23.9 98.00.1
5e 118.62.8[c] 111.48.9 115.37.6 101.51.6 109.83.7 93.95.5 92.15.1 88.615.2 91.85.6 82.22.9[c]
5 f 115.48.5 102.52.3 101.51.6 88.71.6[c] 96.012.7 95.41.7 74.43.2[c] 84.82.5[b] 86.99.4 80.52.8[c]
6d 89.93.4 90.86.3 98.35.3 95.25.0 88.44.1 83.45.6 95.710.0 85.68.9 103.88.1 105.43.4
6 f 95.49.0 100.52.4 106.19.9 100.61.3 106.24.1 111.18.1 106.513.1 88.810.4 98.55.2 91.75.9
[a] Data are presented as mean standard deviation; n3. [b] p<0.05, [c] p<0.001 indicate significant increases or decreases compared to the untreated
control cells according to a two-tailed student t-test with unequal variances.&&ok?&&
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To allow a more thorough interpretation of the results ob-
tained by screening of the b-enaminone analogues and dihy-
dropyridin-4-ones (produced during current and previous stud-
ies),[7] multivariate statistics including hierarchical clustering
analysis (Figure S2) and principal component analysis were
used to find correlations between the chemical structures and
biological activities and to suggest suitable side chains for
good antiproliferative activity.[27] These analyses were applied
to curcumin (Cur), bisdemethoxycurcumin (Bis), pyridin-3-yl
curcuminoid 2, and acetylated curcumin 10 as the mother
compounds for b-enaminones and dihydropyridin-4-ones (32
derivatives, Figure 2a). The multivariate statistics were compu-
tationally performed using the SPSS program (version 24).[28] To
gather more information, principal component analysis (PCA)
was performed to reveal the structural features of their activity.
Thus, a factorial analysis (PCA) was also performed in SPSS sta-
tistics. It was observed that the two major principle compo-
nents explained 46% of the variance between the different
compounds. If the variables are displayed in a 2D plot based
on these two principal components, we can see that three
clusters are formed. Cluster 1 contains antioxidant activity and
ROS activity for the CHO-K1 and EA.hy926 cell lines. Cluster 2
consists of the MTT data of all cell lines, and cluster 3 contains
water solubility and ROS data of the intestinal Caco-2 and HT-
29 cell lines. On the basis of these results, we may suggest
that the biological behavior of the curcuminoids is mainly
driven by water solubility (PCA1, 30.6% of variance) and (anti)-
oxidant activity (PCA2, 15.9% of variance). Secondly, whereas
the MTT data are similar between cell lines, clear cell-line-de-
pendent behavior is visible for the intracellular antioxidant ca-
pacity, because the ROS data for intestinal and nonintestinal
cells are positioned in opposite fields along the PCA1 axis,
which may correspond with water solubility. We hypothesize
that for nonintestinal cell lines, PCA1 (corresponding with solu-
bility) determines the anticancer activity because viability
(MTT) and ROS are in two opposite fields in the plot along the
PCA1 axis. On the basis of existing literature, this may be ex-
plained by the absorption characteristics of the compound,
which may be dominated by passive diffusion,[29] as hydropho-
bic compounds are more absorbed through the cell mem-
brane. However, for intestinal cell lines, it is PCA2 (correspond-
ing with the antioxidant activity of the compounds) that trig-
gers the anticancer effect because viability and ROS are posi-
tioned in opposite fields along this axis. This can be explained
by the fact that intestinal cells are quite robust and have a di-
versity in transporters for phenolics,[30] so that hydrophobicity
is not exclusively necessary for bioavailability. If the com-
pounds are displayed in a 2D plot based on these two princi-
Figure 2. a) Structures of b-enaminones and dihydropyridin-4-ones 5–9. b) Principle component analysis (PCA) plot based on FRAP antioxidant, solubility, the
IC50 of the MTT assay, and ROS on the CHO, EA.hy926, HT-29, and Caco-2 cell lines. c) Factor scores based on the PCA of the FRAP antioxidant, solubility, the
IC50 of the MTT assay, and ROS on the CHO, EA.hy926, HT-29, and Caco-2 cell lines categorized by ten different side chains on either the b-enaminones or di-
hydropyridin-4-ones (see structures in the Supporting Information), which are indicated by colors; triangles represent mother compounds, circles represent b-
enaminones, and squares represent dihydropyridin-4-ones.
ChemistryOpen 2017, 00, 0 – 0 www.chemistryopen.org  2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim6
 These are not the final page numbers!
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
35 35
36 36
37 37
38 38
39 39
40 40
41 41
42 42
43 43
44 44
45 45
46 46
47 47
48 48
49 49
50 50
51 51
52 52
53 53
54 54
55 55
56 56
57 57
pal components, we see that PCA1 (solubility) triggers the sep-
aration of the compounds by the hydrophilicity of the side
chain, as nonpolar aliphatic b-enaminones are clustered in the
left space and polar aliphatic b-enaminones are clustered in
the right space. Hence, these hydrophobic side chains mainly
have an anticancer effect on EA.hy926 and CHO-K1 cells. For
hydrophilic side chains, the effect is mainly triggered by PCA2
(antioxidant capacity) in intestinal cells. This can be explained
by the presence of either a vanillyl or 4-hydroxyphenyl moiety
in the targeted compounds (polar and nonpolar side chains),
which contain hydroxy groups displaying antioxidant proper-
ties. To maintain the antioxidant capacity, we suggest that a
compound that contains a phenolic moiety should be con-
structed, as it may provide better activity. On the basis of the
latter plot, two possibilities to improve bioavailability or bioac-
tivity can be proposed. The first one is that polar amines can
increase water solubility, which may be linked to better/poor
bioavailability (cell dependence); the second one is that alkyla-
mines can increase cytotoxicity (low IC50 values), which may be
linked to higher bioactivity in terms of antiproliferative effects
and ROS induction. To investigate the impact of side chains
and the aromatic moiety as key elements in terms of stability
and water-solubility improvement in biological media, we dis-
play the curcuminoids by the substituted side chains in Fig-
ure 2a, c. Compounds 5c–f, 6d, 6 f, 8 i, 9a, and 9b, substituted
by either a methoxy- or hydroxyalkylamine, are clustered to-
gether in the right space (Figure 2c), generally providing high
solubility and high cytotoxicity. Remarkably, cyclohexyl/isobu-
tyl-substituted b-enaminones (5a, 5b, 7b, 8c, 8 f, 8k, 8 l, and
8m) showed better activity than curcumin, with slightly im-
proved water solubility (5a, 7b, 8c, 8 f, 8k, 8 l, and 8m) or
better solubility (5b). Moreover, compounds 7a, 7c, 7d, 8d,
and 8e showed activity comparable to that of mother com-
pounds Cur and 10, with moderately improved water solubility.
Besides, 8a and 8b demonstrated bioactivity that was better
than or comparable to that of curcumin (Cur). On the other
hand, dihydropyridin-4-ones 6d, 6 f, and 9a–c, bearing polar
aliphatic side chains, are distributed in the right space (PCA1,
solubility) without exhibiting any activity relative to their
mother compounds (Cur, Bis, and 2). Moreover, b-enaminones
5c–f, 8g–j, and 8o--q, bearing polar aliphatic side chains,
showed moderate to good water solubility with either compa-
rable or lower activity. This information could suggest that
alkyl side chains (n-propyl, n-butyl, allyl, isobutyl, sec-butyl, and
cyclohexyl), as demonstrated in our b-enaminone research,[7]
could be of benefit for further investigation of curcumin by
using a similar platform. The improvement in water solubility is
an important factor to address the classical problem of curcu-
min, but compounds that show high solubility could have
compromised biological activity. This could imply that polar b-
enaminones cannot pass the hydrophobic cell membrane of
intestinal cells, thereby leading to low cytotoxicity.[31] Neverthe-
less, b-enaminone analogues display improved compound sta-
bility, which addresses another problem related to curcumin.
3. Conclusions
In summary, we successfully synthesized 2–4 as three new
(pyridine-, indole-, and pyrrole-based) aza-heteroaromatic cur-
cumin analogues and 5a–f as six novel aza-heteroaromatic b-
enaminones. To obtain pyridine b-enaminone analogues 5, an
optimized microwave irradiation approach was performed by
using montmorillonite K10 clay. In some cases, this method
also provided access to dihydropyridin-4-ones 6d and 6 f by
cyclization. As expected on the basis of previous observations,
the installation of the central b-enaminone moiety en route to
N-alkyl or N-hydroxy/methoxyalkyl b-enaminone derivatives 5
(significantly) increased the water solubility relative to that of
the parent compound. Moreover, the water solubility of aza-
heteroaromatic curcumin derivatives 2–4 was also slightly in-
creased relative to that of curcumin. Biologically, three new
aza-aromatic curcumin derivatives (i.e. compounds 2–4), six b-
enaminones (i.e. compounds 5a–f), and two dihydropyridin-4-
ones (i.e. compounds 6d and 6 f) were evaluated for their in-
tracellular and chemical antioxidant properties and their cyto-
toxicity. Bis-indole 3 and bis-pyrrole 4 showed moderate anti-
oxidant properties compared to curcumin (according to the
ferric reducing antioxidant power assay), whereas bis-pyridine
2 did not. Cell-based experiments were performed by using
five different cancer cell lines (HepG2, EA.hy926, Caco-2 and
HT-29, and CHO-K1). With regard to the mitochondrial activity
and protein content, aza-heteroaromatic curcumin derivatives
2–4 showed higher activity than curcumin, and in some cell
lines they showed activity comparable to that of the positive
control doxorubicin. New pyridine b-enaminones 5a–f proved
to have either moderate bioactivity or bioactivity comparable
to that of curcumin. As a result of intracellular ROS generation,
aza-heteroaromatic curcumin compounds 2–4 showed a signif-
icant increase in intracellular ROS production, suggesting that
these molecules may induce cytotoxic effects through ROS-
mediated apoptosis pathways. On the other hand, compounds
5a–f showed slight increases or decreases in ROS generation,
whereas pyridinones 6d and 6 f displayed no significant ROS
variation compared to nontreated cells. In this work, we initiat-
ed a valuable incentive for exploring new curcumin analogues
bearing different aza-heteroaromatic and b-enaminone moiet-
ies that could lead to promising candidates in the framework
of oxidative-related stress disease developments. Moreover, a
structure–activity relationship study using multivariate statistics
analysis showed that nonpolar aliphatic side chains demon-
strated better activity than polar aliphatic side chains, which
explicitly relates to their water-solubility profiles. The highly
soluble b-enaminone derivatives (bearing a polar aliphatic
moiety) showed an inverted relationship concerning cytotoxici-
ty. Therefore, on the basis of our results, we suggest that ali-
phatic amines (allyl, n-butyl, isobutyl, sec-butyl, n-propyl, cyclo-
hexyl) should be used for further development to contribute
to curcumin medicinal chemistry. Biologically active N-alkyl b-
enaminone aza-aromatic curcuminoids thus offer a desirable
balance between good solubility and significant bioactivity.
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Experimental Section
Chemistry
1H NMR spectra were recorded at 400 MHz (Bruker Avance III Nano-
bay) with CDCl3, [D6]DMSO, or [D4]methanol as solvent.
13C NMR
spectra were recorded at 100.6 MHz (Bruker Avance III Nanobay)
with CDCl3, [D6]DMSO, or [D4]methanol as solvent. Low-resolution
mass spectra were recorded by injection with an Agilent 1100
Series LC/MSD type SL mass spectrometer with electrospray ioniza-
tion (ESI, 70 eV) and by using a mass-selective detector (quadru-
pole). Upon analyzing crude reaction mixtures, the mass spectrom-
eter was preceded by a HPLC reverse-phase column with a diode
array UV/Vis detector. High-resolution mass spectra were obtained
with an Agilent Technologies 6210 time-of-flight mass spectrome-
ter (TOFMS) equipped with ESI/APCI-multimode source. IR spectra
were measured with a Fourier-transform infrared spectrophotome-
ter (The IRaffinity-1S). Melting points of crystalline compounds
were measured with a Kofler Bench, type WME Heizbank of
Wagner & Munz. Microwave reactions were performed with a CEM
Discover microwave at fixed temperature. The purity of all tested
compounds was assessed by 1H NMR spectroscopy and/or HPLC
analysis, confirming a purity of 95%.
Representative Procedure for the Synthesis of Aza-Aromatic
Curcumins 2–4
Acetylacetone (1; 20 mmol, 2.04 mL) was added to a solution of
B2O3 (696 mg, 20 mmol, 1 equiv.) in ethyl acetate or acetonitrile
(60 mL). This mixture was stirred at 50 8C for 1 h. Then, pyridine-3-
carboxaldehyde (3.75 mL, 40 mmol, 2 equiv.) and tributyl borate
[n(BuO)3B; 6.53 mL, 40 mmol, 2 equiv.] were added, and the mix-
ture was further stirred at 50 8C for 10 min. Afterwards, either n-bu-
tylamine (0.99 mL, 10 mmol, 0.5 equiv.) or piperidine (0.99 mL,
10 mmol, 0.5 equiv.) in ethyl acetate or acetonitrile (10 mL) was
added dropwise over 1 h, after which the mixture was stirred until
the reaction reached maximum conversion at 80 8C, as determined
by LC–MS.
For EtOAc as the solvent, after cooling to room temperature, 20%
aq acetic acid (100 mL) was added, and the mixture was further
stirred at room temperature for 1 h. The mixture was then washed
with a saturated solution of sodium bicarbonate (350 mL), and
the aqueous phase was extracted with ethyl acetate (230 mL).
The combined organic phase was washed with water and then
dried (magnesium sulfate), filtered, and concentrated under re-
duced pressure. Column chromatography (SiO2, EtOAc/MeOH 19:1)
afforded compound 2 (5.56 g, 50%). Upon using acetonitrile,
boron decomplexation was first performed for 1 h followed by
evaporation and washing with a saturated solution of sodium bi-
carbonate to quench the excess amount of acid and to obtain a
dark red solid. The dark red solid was then subjected to purifica-
tion by reverse-phase column chromatography (acetonitrile/water,
gradient conditions from 30 to 100%) to obtain the pure com-
pound. A similar procedure was then applied for compounds 3
and 4 by using indole-3-carboxaldehyde and pyrrole-2-carboxalde-
hyde, respectively.
(1E,4Z,6E)-5-Hydroxy-1,7-di(pyridin-3-yl)hepta-1,4,6-trien-3-one (2):
Yellow crystals (50%); column chromatography [EtOAc/MeOH 19:1;
Rf (SiO2)=0.18]; m.p. 171 8C;
1H NMR (400 MHz, CDCl3): d=5.89
(1H, s), 6.71 (2H, d, J=15.9 Hz), 7.35 (2H, dd, J=8.0, 4.8 Hz), 7.67
(2H, d, J=15.9 Hz), 7.87 (2H, dt, J=8.0, 1.8 Hz), 8.61 (2H, dd, J=
4.8, 1.8H), 8.80 ppm (2H, d, J=1.8 Hz); 13C NMR (100 MHz, CDCl3):
d=102.2, 123.8, 125.8, 130.7, 134.3, 137.2, 149.8, 150.8, 182.8 ppm.
IR (ATR): n˜=3030, 1625, 1571, 1475, 1413 cm1; MS (70 eV): m/z
(%)=279 [M+1]+ (100).
(1E,4Z,6E)-5-Hydroxy-1,7-di(1H-indol-3-yl)hepta-1,4,6-trien-3-one (3):
Dark red crystals (49%); column chromatography [EtOAc/petrole-
um ether 1:1; Rf (SiO2)=0.30]; m.p. 223 8C;
1H NMR (400 MHz,
[D6]DMSO): d=6.41 (s, 1H), 6.72 (2H, d, J=15.8 Hz), 7.22 (4H, qd,
J=13.8, 1.2 Hz), 7.49 (2H, dd, J=6.9, 1.6 Hz), 7.89 (2H, d, J=
15.8 Hz), 7.96–8.00 (4H, m), 11.81 ppm (2H, s) ; 13C NMR (100 MHz,
[D6]DMSO): d=100.5, 112.9, 113.2, 118.7, 120.5, 121.4, 123.1, 125.4,
132.3, 134.8, 138.0, 183.7 ppm. IR (ATR): n˜=3377 (br), 1607,
1572 cm1; MS (70 eV): m/z (%)=355 [M+1]+ (100).
(1E,4Z,6E)-5-Hydroxy-1,7-di(1H-pyrrol-2-yl)hepta-1,4,6-trien-3-one
(4): Orange solid (66%); column chromatography [EtOAc/petrole-
um ether 1:1; Rf (SiO2)=0.67]; m.p. 200 8C;
1H NMR (400 MHz,
[D6]DMSO): d=5.77 (1H, s), 6.19 (2H, br s), 6.46 (2H, d, J=15.7 Hz),
6.60 (2H, br s), 7.06 (2H, s), 7.44 (2H, d, J=15.7 Hz), 11.55 ppm (2H,
s); 13C NMR (100 MHz, [D6]DMSO): d=100.4, 110.9, 115.0, 117.6,
124.2, 129.5, 130.7, 183.2 ppm; IR (ATR): n˜=3383 (br), 1609,
1585 cm1; MS (70 eV): m/z (%)=255 [M+1]+ (100).
Representative Procedure for the Synthesis of b-Enaminones
5a–f and Dihydropyridin-4-ones 6d and 6 f
(1E,4Z,6E)-5-Hydroxy-1,7-di(pyridin-3-yl)hepta-1,4,6-trien-3-one (2 ;
1 mmol, 278 mg) was dissolved in 2-MeTHF (5 mL) in a 10 mL mi-
crowave tube. To this, montmorillonite clay (MK10; 556 mg,
2 equiv. mass) was added as an activator. Isobutylamine (0.50 mL,
5 mmol, 5 equiv.) and acetic acid (0.14 mL, 2.4 mmol, 2.4 equiv.)
were then added, and the mixture was stirred at 80 8C for 75 min
under microwave irradiation. At the end of the reaction, the mix-
ture was filtered over Celite, and the filter cake was thoroughly
rinsed with ethanol (300 mL). The filtrate was then concentrated
under reduced pressure until about 30 mL of ethanol remained.
Then, ethyl acetate (300 mL) was added, and the mixture was
washed with a saturated solution of sodium bicarbonate (50 mL).
The aqueous phase was washed with ethyl acetate (230 mL). The
combined organic layer was washed with water, dried (magnesium
sulfate), filtered, and concentrated under reduced pressure.
Column chromatography (SiO2, EtOAc/MeOH 9:1) afforded
(1E,4Z,6E)-5-isobutylamino-1,7-di(pyridin-3-yl)hepta-1,4,6-trien-3-
one (5a ; 79.9 mg, 24%). A similar procedure was then applied for
b-enaminones 5b–f and dihydropyridin-4-ones 6d and 6 f. The re-
actions were performed by using ethanol instead of 2-MeTHF to
afford the expected products. The crude products were subjected
to purification by normal-phase column chromatography (SiO2,
EtOAc/MeOH 9:1) to obtain expected compounds 5b, 5c, and 5e.
For compounds 5d, 5 f, 6d, and 6 f, reverse-phase column chroma-
tography (acetonitrile/water, gradient conditions from 10 to 100%)
was used to purify to obtain the desired compounds.
(1E,4Z,6E)-5-Isobutylamino-1,7-di(pyridin-3-yl)hepta-1,4,6-trien-3-
one (5a): Orange oil (24%); column chromatography [EtOAc/
MeOH 19:1; Rf (SiO2)=0.18];
1H NMR (400 MHz, CDCl3): d=1.05
(6H, d, J=6.5 Hz), 1.96 (1H, nonet, J=6.5 Hz), 3.25 (2H, ~ t, J=
6.5 Hz), 5.55 (1H, s), 6.84 (1H, d, J=15.8 Hz), 6.92 (1H, d, J=
16.1 Hz), 7.26 (1H, d, J=16.1 Hz), 7.29 (1H, dd, J=8.0, 4.5 Hz), 7.35
(1H, dd, J=8.0, 4.5 Hz), 7.53 (1H, d, J=15.8 Hz), 7.83 (2H, d, J=
8.0 Hz), 8.54 (1H, d, J=4.5 Hz), 8.60 (1H, d, J=4.5 Hz), 8.75–8.78
(2H, m), 11.67 ppm (1H, t, J=6.0 Hz); 13C NMR (100 MHz, CDCl3):
d=20.2, 29.4, 51.5, 94.1, 122.8, 123.6, 123.8, 130.7, 131.2, 131.7,
133.5, 133.7, 134.0, 134.1, 149.1, 149.4, 149.8, 150.3, 162.4,
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184.8 ppm; IR (ATR): n˜=3032, 2958, 1641, 1575, 1544, 1508,
1413 cm1; MS (70 eV): m/z (%)=334 [M+1]+ (100).
(1E,4Z,6E)-5-Cyclohexylamino-1,7-di(pyridin-3-yl)hepta-1,4,6-trien-3-
one (5b): Yellow crystals (6%); column chromatography [EtOAc/
MeOH 9:1; Rf (SiO2)=0.26] and recrystallization (MeOH); m.p.
174 8C; 1H NMR (400 MHz, CDCl3): d=1.30–1.65 (6H, m), 1.80–1.84
(2H, m), 1.94–1.97 (2H, m), 3.56–3.63 (1H, m), 5.52 (1H, s), 6.83
(1H, d, J=15.8 Hz), 6.94 (1H, d, J=15.9 Hz), 7.27 (1H, d, J=
15.9 Hz), 7.29 (1H, dd, J=7.9, 4.8 Hz), 7.35 (1H, dd, J=7.9, 4.8 Hz),
7.52 (1H, d, J=15.8 Hz), 7.81–7.84 (2H, m), 8.54 (1H, dd, J=4.8,
1.8 Hz), 8.60 (1H, dd, J=4.8, 1.8 Hz), 8.75 (1H, d, J=1.8 Hz), 8.77
(1H, d, J=1.8 Hz), 11.71 ppm (1H, d, J=8.1 Hz); 13C NMR (100 MHz,
CDCl3): d=24.2, 25.3, 33.8, 52.2, 93.9, 122.7, 123.6, 123.8, 130.7,
131.3, 131.8, 133.4, 133.7, 133.9, 134.1, 149.1, 149.4, 149.8, 150.3,
161.1, 184.6 ppm; IR (ATR): n˜=3361 (br), 2929, 1633, 1571, 1510,
1415 cm1; MS (70 eV): m/z (%)=360 [M+1]+ (100).
(1E,4Z,6E)-5-(2-Methoxyethylamino)-1,7-di(pyridin-3-yl)hepta-1,4,6-
trien-3-one (5c): Orange-red viscous oil (16%); column chromatog-
raphy [EtOAc/MeOH 9:1; Rf (SiO2)=0.12];
1H NMR (400 MHz, CDCl3):
d=3.43 (3H, s), 3.60–3.61 (4H, m), 5.57 (1H, s), 6.84 (1H, d, J=
15.8 Hz), 7.02 (1H, d, J=16.1 Hz), 7.24 (1H, d, J=16.1 Hz), 7.30 (1H,
dd, J=7.9, 4.8 Hz), 7.34 (1H, dd, J=7.9, 4.8 Hz), 7.53 (1H, d, J=
15.8 Hz), 7.81–7.85 (2H, m), 8.54 (1H, dd, J=4.8, 1.9 Hz), 8.60 (1H,
dd, J=4.8, 1.9 Hz), 8.74 (1H, d, J=1.9 Hz), 8.78 (1H, d, J=1.9 Hz),
11.55 ppm (1H, br s); 13C NMR (100 MHz, CDCl3): d=43.8, 59.3, 71.7,
94.4, 123.2, 123.6, 123.7, 130.6, 131.3, 131.7, 133.7, 133.8, 133.9,
134.1, 149.2, 149.5, 149.8, 150.3, 162.5, 185.2 ppm; IR (ATR): n˜=
3053, 2922, 1645, 1568, 1506, 1425, 1411 cm1; MS (70 eV): m/z
(%)=336 [M+1]+ (100).
(1E,4Z,6E)-5-(3-Methoxypropylamino)-1,7-di(pyridin-3-yl)hepta-1,4,6-
trien-3-one (5d): Orange oil (4%); normal-phase column chroma-
tography [EtOAc/MeOH 9:1; Rf (SiO2)=0.13] and reverse-phase
column chromatography (CH3CN/H2O 30:70 to 100:0),
1H NMR
(400 MHz, CDCl3): d=1.93 (2H, quint, J=6.0 Hz), 3.36 (3H, s), 3.50
(2H, t, J=6.0 Hz), 3.55 (2H, q, J=6.0 Hz), 5.57 (1H, s), 6.84 (1H, d,
J=15.8 Hz), 7.01 (1H, d, J=16.2 Hz), 7.27 (1H, d, J=16.2 Hz), 7.30
(1H, dd, J=7.9, 4.8 Hz), 7.35 (1H, dd, J=8.1, 4.8 Hz), 7.52 (1H, d,
J=15.8 Hz), 7.82–7.86 (2H, m), 8.54 (1H, dd, J=4.8, 1.5 Hz), 8.60
(1H, dd, J=4.8, 1.5 Hz), 8.75 (1H, d, J=1.5 Hz), 8.78 (1H, d, J=
1.5 Hz), 11.55 ppm (1H, t, J=6.0 Hz); 13C NMR (100 MHz, CDCl3):
d=30.5, 40.6, 58.8, 69.0, 93.9, 122.7, 123.6, 123.7, 130.7, 131.2,
131.7, 133.57, 133.64, 134.0, 134.1, 149.3, 149.5, 149.8, 150.3, 162.5,
184.9 ppm; IR (ATR): n˜=3226 (br), 3032, 2929, 1710, 1639, 1566,
1512, 1413 cm1; MS (70 eV): m/z (%)=350 [M+1]+ (100).
(1E,4Z,6E)-5-(2-Hydroxyethylamino)-1,7-di(pyridin-3-yl)hepta-1,4,6-
trien-3-one (5e): Red-brown crystals (12%); column chromatogra-
phy [EtOAc/MeOH 9:1; Rf (SiO2)=0.05]; m.p. 83 8C;
1H NMR
(400 MHz, CDCl3): d=3.61 (2H, q, J=5.4 Hz), 3.88 (2H, t, J=5,4 Hz),
5.59 (1H, s), 6.83 (1H, d, J=15.9 Hz), 7.03 (1H, d, J=16.2 Hz), 7.26
(1H, d, J=16.2 Hz), 7.30 (1H, dd, J=7.8, 4.8 Hz), 7.34 (1H, dd, J=
7.7, 4.8 Hz), 7.52 (1H, d, J=15.9 Hz), 7.82–7.85 (2H, m), 8.54 (1H,
dd, J=4.8, 1.6 Hz), 8.59 (1H, dd, J=4.8, 1.6 Hz), 8.74 (1H, d, J=
1.6 Hz), 8.77 (1H, d, J=1.6 Hz), 11.61 ppm (1H, t, J=5.4 Hz);
13C NMR (100 MHz, CDCl3): d=45.9, 62.1, 94.6, 123.0, 123,6, 123.8,
130.5, 131.1, 131.6, 133.7, 133.9, 134.1, 134.2, 149.2, 149.4, 149.8,
150.4, 162.8, 185.3 ppm; IR (ATR): n˜=3292 (br), 3045, 2927, 1672,
1641, 1568, 1510, 1490, 1413 cm1; MS (70 eV): m/z (%)=322
[M+1]+ (100).
(1E,4Z,6E)-5-(3-Hydroxypropylamino)-1,7-di(pyridin-3-yl)hepta-1,4,6-
trien-3-one (5 f): Dark-brown oil (16%); reverse-phase chromatogra-
phy, tR=2.93 min (gradient conditions, 10% acetonitrile in water to
100% acetonitrile, 5 min, flow rate: 1 mLmin1) ; 1H NMR (400 MHz,
[D4]methanol): d=1.91 (2H, quint, J=6.4 Hz), 3.67 (2H, t, J=
6.8 Hz), 3.73 (2H, t, J=6.0 Hz), 5.80 (1H, s), 7.04 (1H, d, J=16.0 Hz),
7.33 (1H, d, J=16.2 Hz), 7.44 7.54 (4H, m), 8.10 (1H, dt, J=7.9
and 1.6 Hz), 8.20 (1H, dt, J=7.7, 1.8 Hz), 8.11 (1H, d, J=8.0 Hz),
8.20 (1H, d, J=8.0 Hz), 8.74 (1H, d, J=1.5 Hz), 8.80 ppm (1H, s);
13C NMR (100 MHz, [D4]methanol): d=32.7, 39.9, 58.2, 93.4, 122.6,
124.1, 124.2, 131.4, 132.1, 132.4, 132.5, 134.6, 134.66, 134.72, 148.3,
148.5, 148.7, 149.2, 163.6, 184.6 ppm; IR (ATR): n˜=3309 (br), 2937,
1641, 1577, 1531, 1417 cm1; MS (70 eV): m/z (%)=336 [M+1]+
(100).
(E)-1-(3-Methoxypropyl)-2-(pyridin-3-yl)-6-[2-(pyridin-3-yl)vinyl]-2,3-
dihydropyridin-4(1H)-one (6d): Brown oil (16%); reverse-phase
chromatography, tR=0.54 min (30% acetonitrile in water to 100%
acetonitrile, 5 min, flow rate: 1 mLmin1) ; 1H NMR (400 MHz,
[D4]methanol): d=1.93–1.96 (2H, m), 2.60 (1H, d, J=16.8 Hz), 3.30
(3H, s), 3.26–3.34 (2H, m,), 3.44–3.48 (2H, m), 4.04–4.11 (1H, m),
5.11 (1H, dd, J=7.6, 1.6 Hz), 5.42 (1H, s), 7.44–7.54 (4H, m), 7.85
(1H, d, J=7.9 Hz), 8.18 (1H, d, J=7.9 Hz), 8.51 (1H, d, J=4.4 Hz),
8.54 (2H, br s), 8.81 ppm (1H, s); 13C NMR (100 MHz, [D4]methanol):
d=30.6, 42.5, 49.4, 58.9, 60.2, 70.0, 98.0, 125.4, 125.6, 133.5, 136.3,
136.37, 136.39, 136.6, 148.5, 149.6, 149.8, 150.6, 164.1, 191.6 ppm;
IR (ATR): n˜=2926, 1620 1531, 1479, 1421 cm1; MS (70 eV): m/z
(%)=350 [M+1]+ (100).
(E)-1-(3-Hydroxypropyl)-2-(pyridin-3-yl)-6-[2-(pyridin-3-yl)vinyl]-2,3-
dihydropyridin-4(1H)-one (6 f): Dark-orange oil (7%); reverse-phase
chromatography, tR=2.62 min (gradient conditions, 10% acetoni-
trile in water to 100% acetonitrile, 5 min, flow rate: 1 mLmin1) ;
1H NMR (400 MHz, [D4]methanol): d=1.84–1.94 (2H, m), 2.58 (1H,
d, J=16.8 Hz), 3.25–3.38 (2H, m), 3.63 (2H, t, J=5.6 Hz), 4.00–4.10
(1H, quint, J=7.2 Hz), 5.13 (1H, dd, J=7.8, 2.1 Hz), 5.40 (1H, s),
7.43–7.51 (4H, m), 7.84 (1H, dt, J=8.0, 2.0 Hz), 8.49 (1H, dt, J=8.0,
2.0 Hz), 8.50 (1H, dd, J=4.8, 0.8 Hz), 8.51 (1H, d, J=1.1 Hz), 8.53
(1H, d, J=1.3 Hz), 8.80 ppm (1H, d, J=1.6 Hz); 13C NMR (100 MHz,
[D4]methanol): d=33.2, 42.5, 49.4, 59.3, 60.4, 98.1, 125.4, 125.5,
133.5, 136.3, 136.5, 136.6, 148.5, 149.6, 149.9, 150.6, 164.2,
191.5 ppm; IR (ATR): n˜=3265 (br), 1591, 1517, 1492, 1415 cm1; MS
(70 eV): m/z (%)=336 [M+1]+ (100).
Biological Studies
General
MEM nonessential amino acid solution (NEAA), 2,2-diphenyl-1-pic-
rylhydrazyl (DPPH), penicillin/streptomycin (P/S), Trolox, and 2,7-di-
chlorofluorescein diacetate were purchased from Sigma–Aldrich,
whereas 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) and trypan blue were obtained from Amresco. Trypsin/
ethylenediaminetetraacetic acid (EDTA) solution and Dulbecco’s
phosphate-buffered saline (PBS , no calcium and no magnesium)
were obtained from Life Technologies, and fetal bovine serum
(FBS) was obtained from Greiner Bio-one. All cell lines, Caco-2 (col-
orectal adenocarcinoma), HepG2 (hepatocellular carcinoma), CHO
(Chinese hamster ovary), HT-29 (colorectal adenocarcinoma), and
EA.hy926 (endothelial), were obtained from ATCC. These cell lines
were cultivated and maintained in a growth medium containing
Dulbecco’s modified Eagle medium (DMEM)+glutamax, 1% NEAA,
1% P/S, and 10% FBS. During the MTT experiment, serum-free
medium was used to avoid interferences. Each compound or posi-
tive control was dissolved in DMSO to prepare the 25 mm stock so-
lution for both cytotoxicity and antioxidant tests. The stock solu-
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tions were aliquoted and stored in a refrigerator for the further
replicate experiment.
Cytotoxicity Activity: MTT Experiments
Throughout the experiment, standard procedures were used to
maintain all cell lines at 37 8C with 95% humidity and 10% CO2.
Using adherent cells, the MTT assay was performed to determine
the number of viable cells in this assay. Briefly, 2104 cells sus-
pended in DMEM (200 mL) were first inoculated into each well of a
96-well microplate and were incubated for 24 h. Then, the medium
in each well was removed and an equal volume of serum-free
medium (200 mLwell1) containing either test compound or posi-
tive control (doxorubicin hydrochloride, DOX) at various concentra-
tions was added for 72 h. Each compound was performed in tripli-
cate. Afterwards, the cell viability was determined by removing
100 mL of medium and adding 20 mL of MTT solution (5 mgmL1 in
PBS) followed by 2 h of incubation. Finally, DMEM with MTT solu-
tion was then removed and replaced with DMSO to dissolve the
formazan crystal. The 96-well microplate was then measured at l=
570 nm by using a Spectramax (Molecular Devices) microplate
spectrophotometer. For data analysis, the percentage of surviving
cells after exposure to various concentrations of each test com-
pound for 72 h was calculated to obtain the IC50 value of each
compound.
Protein Content (SRB) Analysis
The SRB assay is based on the measurement of cellular proteins.
Sulforhodamine B can bind electrostatically with basic amino-acid
residues if the cells are fixed with trichloroacetic acid (TCA) and
can be solubilized by weak bases. Because of this quantitative
staining capacity of SRB, the assay is used to screen for cytotoxicity
and cell density. The cells were seeded at a concentration of 2
104 cells per well for 24 h and were treated with or without (con-
trol) compounds. Three days after this treatment, the cells were
fixed by adding 50% TCA in Milli-Q water (50 mL) for 1 h in the
cold room, 4 8C. The plate was washed at least three times with
tap water and was then dried, after which the cells were stained
with SRB solution (0.4% sulforhodamine B in 1% glacial acetic
acid) at 4 8C. After 30 min, the plate was rinsed with 1% glacial
acetic acid (5) dried. Sequentially, Tris buffer in a concentration of
10 mm was used to redissolve the stain. Finally, the absorbance
was measured using the microplate spectrophotometer at a wave-
length of 490 nm. Each condition was performed in triplicate.
Reactive Oxygen Species (ROS) Assay
The experiments were performed in an incubator at 37 8C with
10% CO2. Seeding of a concentration of 210
4 cells per well in
DMEM was performed in a black 96-well plate with transparent
bottom. After 24 h, the confluent cells were equally treated with or
without the compounds at 10 and 1 mm in serum-free medium
(200 mL). Then, after removal of the medium, the cells were
washed with PBS buffer followed by the addition of 2,7-dichloro-
fluorescein diacetate (DCFH-DA, 20 mm) for a 30 min incubation
period. Thereafter, DCFH-DA was removed, and the cells were
washed with PBS. Afterwards, DMEM without phenol red medium
was added in equal volume for 1 h of incubation. Finally, the black
96-well plates were measured for fluorescence with a Gemini XPS
Microplate Reader with an excitation of l=485 nm and an emis-
sion of l=535 nm. Afterwards, the plate experiments were contin-
ued to evaluate the protein content with a similar protocol as for
the SRB assay described above. The SRB assay was used to normal-
ize the results, which were related to the amount of protein pres-
ent in each well.
Chemical Antioxidant Capacity: DPPH Scavenger
The 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical is commonly used
to determine antioxidant activity. First, DPPH was freshly prepared
at 5 mgmL1 in DMSO. Then, DPPH was diluted into 200 mm in
MeOH for antioxidant measurements. In addition, stock solutions
of test compounds were also properly diluted in MeOH at various
concentrations. Afterwards, 200 mm DPPH solution (100 mL) was
then added into 96-well microplates. Subsequently, test compound
(100 mL) at various concentrations and blanks without derivative
were individually added into each well and vigorously mixed for
30 min in the dark chamber at 30 8C. After incubation in darkness,
the solutions were measured at l=515 nm by using a Spectramax
microplate spectrophotometer. The required concentration to
reduce the absorbance by 50% (EC50) was calculated from the
equation obtained by fitting the linear part of the absorption
curves. A positive compound, namely, Trolox, was used as refer-
ence. The results are the mean values determined from at least
three independent experiments for each compound [Eq. (1)]:
I ½% ¼ ½AbsBðAbsSAbsSCÞ
AbsB
 100
in which &&I is - please define&&, AbsB is the absorption of
blank DPPH in MeOH, AbsS is the absorption of sample with
DPPH at various concentrations, and AbsSC is absorption of
sample control without DPPH at various concentrations.
Ferric Reducing Ability of Plasma (FRAP) Assay
An acetate buffer of 300 mm was prepared by adding sodium ace-
tate trihydrate (3.1 g) to acetic acid (16 mL) and was diluted to
1000 mL with Milli-Q water. A TPTZ (2,4,6-tripyridyl-s-triazine) solu-
tion of 10 mm was prepared by adding TPTZ (0.156 g) to ethanol
(50 mL). Lastly, a 20 mm solution of iron(III) chloride hexahydrate
was prepared by mixing FeCl3·6H2O (0.5404 g) with 37% HCl
(2 mL) and Milli-Q water (98 mL). The TPTZ and iron solutions were
freshly prepared on the day of the assay. These three mixtures
were added in a 10:1:1 ratio to obtain the FRAP reagent. Finally,
samples (100 mL) were mixed with the FRAP reagent (900 mL) and
after 4 min the absorbance was measured at l=593 nm with a
Spectramax microplate spectrophotometer. Trolox was used as a
standard, and the FRAP value was calculated as Trolox equiva-
lent [mm] through linear regression of the Trolox standard curve.
Water Solubility and Stability Measurements
The shake flask method is commonly used to measure aqueous
solubility.[12] The test compounds were first measured for maximum
absorbance by using the liquid chromatography (LC) technique
using Ascentis Express C18, HPLC column 3 cm4.6 mm, 2.7 mm
(LC method for 5 min at flow rate 1 mLmin1 during the gradient
elution). Afterwards, the standard curves were prepared from vari-
ous concentrations of the test compounds. In this experiment, a
sodium phosphate buffered solution at pH 6.8 was used to per-
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form the solubility test of each b-enaminone compound. An excess
amount of a solid compound was added into 1 mL of the phos-
phate-buffered solution (pH 6.8). The experiment was divided into
two time points. The first one was fixed at 90 min under a sonica-
tor bath at 37 8C and the second one at 30 min under a sonicator
bath at 37 8C followed by 23 h of incubation at 300 rpm and soni-
cation for another 30 min. Both time points of each sample were
centrifuged at 14000 rpm for 5 min. Then, all compounds were fil-
tered (0.2 mm) at 37 8C. Subsequently, the solutions were diluted in
DMSO to avoid precipitation of the compounds at room tempera-
ture. Each compound was individually measured at its maximum
absorbance. Finally, the solubility values were calculated from the
linear equations of each standard curve. The experiment was inde-
pendently triplicated.
Acknowledgements
The authors are indebted to Ghent University and to the Lotus+
Erasmus Mundus Programme of the European Union for financial
support.
Conflict of Interest
The authors declare no conflict of interest.
Keywords: biological activity · cytotoxicity · enaminones ·
nitrogen heterocycles · oxidative stress
[1] H. J. J. Pabon, Rec. Trav. Chim. Pays Bas 1964, 83, 379–386.
[2] a) U. Pedersen, P. B. Rasmussen, S.-O. Lawesson, Liebigs Ann. Chem.
1985, 1985, 1557–1569; b) M. A. Khan, R. El-Khatib, K. D. Rainsford,
M. W. Whitehouse, Bioorg. Chem. 2012, 40, 30–38; c) V. D. John, M. B.
Ummathur, K. Krishnankutty, J. Coord. Chem. 2013, 66, 1508–1518.
[3] a) R. Hanif, L. Qiao, S. J. Shiff, B. Rigas, J. Lab. Clin. Med. 1997, 130, 576–
584; b) K. Mehta, P. Pantazis, T. McQueen, B. B. Aggarwal, Anti-cancer
Drugs 1997, 8, 470–481; c) T. M. Elattar, A. S. Virji, Anticancer Res. 2000,
20, 1733–1738; d) A. Mukhopadhyay, C. Bueso-Ramos, D. Chatterjee, P.
Pantazis, B. B. Aggarwal, Oncogene 2001, 20, 7597–7609; e) D. R. Siwak,
S. Shishodia, B. B. Aggarwal, R. Kurzrock, Cancer 2005, 104, 879–890;
f) Y. G. Lin, A. B. Kunnumakkara, A. Nair, W. M. Merritt, L. Y. Han, G. N.
Armaiz-Pena, A. A. Kamat, W. A. Spannuth, D. M. Gershenson, S. K. Lut-
gendorf, B. B. Aggarwal, A. K. Sood, Clin. Cancer Res. 2007, 13, 3423–
3430.
[4] a) S. D. Deodhar, R. Sethi, R. C. Srimal, Indian J. Med. Res. 1980, 71, 632–
634; b) M. A. Azuine, S. V. Bhide, Nutr. Cancer 1992, 17, 77–83; c) G.
Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, P. S. Srinivas, Planta
Med. 1998, 64, 353–356; d) A. L. Cheng, C. H. Hsu, J. K. Lin, M. M. Hsu,
Y. F. Ho, T. S. Shen, J. Y. Ko, J. T. Lin, B. R. Lin, W. Ming-Shiang, H. S. Yu,
S. H. Jee, G. S. Chen, T. M. Chen, C. A. Chen, M. K. Lai, Y. S. Pu, M. H. Pan,
Y. J. Wang, C. C. Tsai, C. Y. Hsieh, Anticancer Res. 2001, 21, 2895–2900;
e) C. D. Lao, M. T. t. Ruffin, D. Normolle, D. D. Heath, S. I. Murray, J. M.
Bailey, M. E. Boggs, J. Crowell, C. L. Rock, D. E. Brenner, BMC Complemen-
tary Altern. Med. 2006, 6, 10.
[5] a) V. Ravindranath, N. Chandrasekhara, Toxicology 1981, 22, 337–344;
b) R. A. Sharma, H. R. McLelland, K. A. Hill, C. R. Ireson, S. A. Euden, M. M.
Manson, M. Pirmohamed, L. J. Marnett, A. J. Gescher, W. P. Steward, Clin.
Cancer Res. 2001, 7, 1894–1900; c) G. Garcea, D. J. L. Jones, R. Singh,
A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, A. J. Gescher,
D. P. Berry, Br. J. Cancer 2004, 90, 1011–1015; d) P. Anand, A. B. Kunnu-
makkara, R. A. Newman, B. B. Aggarwal, Mol. Pharm. 2007, 4, 807–818;
e) K. M. Nelson, J. L. Dahlin, J. Bisson, J. Graham, G. F. Pauli, M. A. Wal-
ters, J. Med. Chem. 2017, 60, 1620–1637&&ok?&&.
[6] a) A. R. Reddy, P. Dinesh, A. S. Prabhakar, K. Umasankar, B. Shireesha,
M. B. Raju, Mini-Rev. Med. Chem. 2013, 13, 1769–1777; b) A. Vyas, P.
Dandawate, S. Padhye, A. Ahmad, F. Sarkar, Curr. Pharm. Des. 2013, 19,
2047–2069.
[7] a) R. De Vreese, C. Grootaert, S. D’hoore, A. Theppawong, S. Van
Damme, M. Van Bogaert, J. Van Camp, M. D’hooghe, Eur. J. Med. Chem.
2016, 123, 727–736; b) A. Theppawong, R. De Vreese, L. Vannecke, C.
Grootaert, J. Van Camp, M. D’hooghe, Bioorg. Med. Chem. Lett. 2016, 26,
5650–5656.
[8] J. A. Makawana, M. P. Patel, R. G. Patel, Chin. Chem. Lett. 2012, 23, 427–
430.
[9] J. E. Foster, J. M. Nicholson, R. Butcher, J. P. Stables, I. O. Edafiogho, A. M.
Goodwin, M. C. Henson, C. A. Smith, K. R. Scott, Bioorg. Med. Chem.
1999, 7, 2415–2425.
[10] D. Simoni, M. Rizzi, R. Rondanin, R. Baruchello, P. Marchetti, F. P. Invidia-
ta, M. Labbozzetta, P. Poma, V. Carina, M. Notarbartolo, A. Alaimo, N.
D’Alessandro, Bioorg. Med. Chem. Lett. 2008, 18, 845–849.
[11] a) Y. Liu, M. Ye, Q. Wu, L. Wu, J. Xu, Lett. Drug Des. Discovery 2014, 11,
993–999&&ok?&&; b) S. Raghavan, P. Manogaran, K. K. Gadepalli
Narasimha, B. Kalpattu Kuppusami, P. Mariyappan, A. Gopalakrishnan, G.
Venkatraman, Bioorg. Med. Chem. Lett. 2015, 25, 3601–3605.
[12] a) L. Zhou, L. Yang, S. Tilton, J. Wang, J. Pharm. Sci. 2007, 96, 3052–
3071; b) E. Baka, J. E. Comer, K. Takacs-Novak, J. Pharm. Biomed. Anal.
2008, 46, 335–341.
[13] a) I. F. F. Benzie, J. J. Strain, Anal. Biochem. 1996, 239, 70–76; b) G. Litwi-
nienko, K. U. Ingold, J. Org. Chem. 2004, 69, 5888–5896; c) K. Thaipong,
U. Boonprakob, K. Crosby, L. Cisneros-Zevallos, D. Hawkins Byrne, J.
Food Compos. Anal. 2006, 19, 669–675; d) K. Mishra, H. Ojha, N. K.
Chaudhury, Food Chem. 2012, 130, 1036–1043.
[14] a) D. Karunagaran, R. Rashmi, T. R. Kumar, Curr. Cancer Drug Targets
2005, 5, 117–129; b) J. J. Johnson, H. Mukhtar, Cancer Lett. 2007, 255,
170–181; c) A. B. Kunnumakkara, P. Anand, B. B. Aggarwal, Cancer Lett.
2008, 269, 199–225.
[15] P. Sanz, O. M, M. YÇez, J. Elguero, J. Phys. Chem. A 2007, 111, 3585–
3591.
[16] P. Steer, J. Millgard, D. M. Sarabi, S. Basu, B. Vessby, T. Kahan, M. Edner,
L. Lind, Lipids 2002, 37, 231–236.
[17] G. Waris, H. Ahsan, J. Carcinog. 2006, 5, 14–14.
[18] M. L. Circu, T. Y. Aw, Free Radical Biol. Med. 2010, 48, 749–762.
[19] V. Di Matteo, E. Esposito, Curr. Drug Targets : CNS Neurol. Disord. 2003, 2,
95–107.
[20] R. Angelopoulou, G. Lavranos, P. Manolakou, Reprod. Toxicol. 2009, 28,
167–171.
[21] M. Valko, D. Leibfritz, J. Moncol, M. T. Cronin, M. Mazur, J. Telser, Int. J.
Biochem. Cell Biol. 2007, 39, 44–84.
[22] M. Gerber, M. C. Boutron-Ruault, S. Hercberg, E. Riboli, A. Scalbert, M. H.
Siess, Bull. Cancer 2002, 89, 293–312.
[23] T. Atsumi, K. Tonosaki, S. Fujisawa, Arch. Oral Biol. 2006, 51, 913–921.
[24] R. Jger, R. P. Lowery, A. V. Calvanese, J. M. Joy, M. Purpura, J. M. Wilson,
Nutr. J. 2014, 13, 11.
[25] a) S.-Y. Sun, Cancer Biol. Ther. 2010, 9, 109–110; b) M. Halasi, M. Wang,
T. S. Chavan, V. Gaponenko, N. Hay, A. L. Gartel, Biochem. J. 2013, 454,
201–208.
[26] a) T. Atsumi, K. Tonosaki, S. Fujisawa, Anticancer Res. 2007, 27, 363–371;
b) F. Thayyullathil, S. Chathoth, A. Hago, M. Patel, S. Galadari, Free Radi-
cal Biol. Med. 2008, 45, 1403–1412; c) Y. Sanchez, G. P. Simon, E. Calvi-
no, E. de Blas, P. Aller, J. Pharmacol. Exp. Ther. 2010, 335, 114–123;
d) M. B. Chen, X. Y. Wu, G. Q. Tao, C. Y. Liu, J. Chen, L. Q. Wang, P. H. Lu,
Int. J. Cancer 2012, 131, 2487–2498; e) S. U. Gandhy, K. Kim, L. Larsen,
R. J. Rosengren, S. Safe, BMC cancer 2012, 12, 564; f) G. D. Noratto, I. Ju-
tooru, S. Safe, G. Angel-Morales, S. U. Mertens-Talcott, Mol. Nutr. Food
Res. 2013, 57, 1638–1648; g) D. Wang, J. Hu, L. Lv, X. Xia, J. Liu, X. Li,
Oncol. Lett. 2013, 6, 81–85; h) X. Zhang, M. Chen, P. Zou, K. Kanchana,
Q. Weng, W. Chen, P. Zhong, J. Ji, H. Zhou, L. He, G. Liang, BMC cancer
2015, 15, 866.
[27] S. J. Duthie, W. T. Melvin, M. D. Burke, Xenobiotica 1994, 24, 265–279.
[28] H. Abdi, L. J. Williams, Wiley Interdiscip. Rev. Comput. Stat. 2010, 2, 433–
459.
[29] W. N. Dudley, J. G. Benuzillo, M. S. Carrico, Nurs. Res. 2004, 53, 59–62.
[30] H. Yu, Q. Huang, J. Agric. Food Chem. 2011, 59, 9120–9126.
[31] a) G. Williamson, A. J. Day, G. W. Plumb, D. Couteau, Biochem. Soc. Trans.
2000, 28, 16–22; b) Y. Konishi, S. Kobayashi, M. Shimizu, J. Agric. Food
Chem. 2003, 51, 7296–7302; c) S. Gao, M. Hu, Mini-Rev. Med. Chem.
ChemistryOpen 2017, 00, 0 – 0 www.chemistryopen.org  2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim11
These are not the final page numbers! 
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
35 35
36 36
37 37
38 38
39 39
40 40
41 41
42 42
43 43
44 44
45 45
46 46
47 47
48 48
49 49
50 50
51 51
52 52
53 53
54 54
55 55
56 56
57 57
2010, 10, 550–567; d) S. Manzano, G. Williamson, Mol. Nutr. Food Res.
2010, 54, 1773–1780; e) G. R. Velderrain-Rodriguez, H. Palafox-Carlos, A.
Wall-Medrano, J. F. Ayala-Zavala, C. Y. O. Chen, M. Robles-Sanchez, H. As-
tiazaran-Garcia, E. Alvarez-Parrilla, G. A. Gonzalez-Aguilar, Food Funct.
2014, 5, 189–197.
[32] A. M. Calcagno, J. A. Ludwig, J. M. Fostel, M. M. Gottesman, S. V. Ambud-
kar, Mol. Pharm. 2006, 3, 87–93.&&please check– this ref does not
appear to be cited within the text&&
Received: February 27, 2018
Version of record online && &&, 2018
ChemistryOpen 2017, 00, 0 – 0 www.chemistryopen.org  2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim12
 These are not the final page numbers!
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
35 35
36 36
37 37
38 38
39 39
40 40
41 41
42 42
43 43
44 44
45 45
46 46
47 47
48 48
49 49
50 50
51 51
52 52
53 53
54 54
55 55
56 56
57 57
FULL PAPERS
A. Theppawong, T. Van de Walle,
C. Grootaert, M. Bultinck, T. Desmet,
J. Van Camp,* M. D’hooghe*
&& –&&
Synthesis of Novel Aza-aromatic
Curcuminoids with Improved
Biological Activities towards Various
Cancer Cell Lines
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